FIELD: pharmacology.
SUBSTANCE: drug comprises a non-viral plasmid construct carrying a gene coding for hepatocyte growth factor (HGF) and a non-viral plasmid construct carrying a gene coding for angiopoietin-1 (Ang-1). The mentioned plasmid constructs as parts of the drug are taken in a weight ratio from 2:1 to 1:2 and are diluted in physiological solution. In order to implement a method of angiogenesis augmentation in ischemic tissues the mentioned combination drug is injected intramuscularly, directly into the ischemic zone.
EFFECT: invention enables to improve the efficiency of angiogenesis in ischemic tissues due to synergistic effect of using combination of the two constructions metioned above.
15 cl, 9 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HGFopt GENE OF HEPATOCYTE GROWTH FACTOR | 2008 |
|
RU2385936C1 |
| AGPopt GENE OF ANGIOPOIETIN-1 | 2008 |
|
RU2385938C1 |
| MEDICINAL AGENT FOR TREATING HEPATIC FIBROSIS, METHOD FOR PRODUCTION THEREOF AND METHOD OF TREATING HEPATIC FIBROSIS | 2015 |
|
RU2615445C2 |
| GENE-THERAPEUTIC DNA-VECTOR BASED ON GENE-THERAPEUTIC DNA-VECTOR VTVAF17, CARRYING TARGET GENE SELECTED FROM GROUP OF GENES ANG, ANGPT1, VEGFA, FGF1, HIF1Α, HGF, SDF1, KLK4, PDGFC, PROK1, PROK2 TO INCREASE EXPRESSION LEVEL OF SAID TARGET GENES, METHOD FOR PRODUCTION AND USE THEREOF, STRAIN ESCHERICHIA COLI SCS110-AF/VTVAF17-ANG, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-ANGPT1, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-VEGFA, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-FGF1, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-HIF1Α, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-HGF, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-SDF1, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-KLK4, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-PDGFC, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-PROK1, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-PROK2, CARRYING GENE-THERAPEUTIC DNA VECTOR, METHOD FOR PRODUCTION THEREOF, METHOD FOR INDUSTRIAL PRODUCTION OF GENE-THERAPEUTIC DNA VECTOR | 2018 |
|
RU2730664C2 |
| VEGFopt GENE OF HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR | 2008 |
|
RU2385937C1 |
| GENETIC ENGINEERING STRUCTURE FOR ANGIOGENESIS STIMULATION | 2019 |
|
RU2737487C1 |
| METHOD OF PRODUCING DIMERIC FORM OF MUTANT IGA2M1-ISOTYPE IMMUNOGLOBULIN IN MAMMALIAN CELLS | 2023 |
|
RU2822889C1 |
| METHOD OF PRODUCING DIMERIC FORM OF IMMUNOGLOBULIN IGA1-ISOTYPE IN MAMMALIAN CELLS | 2023 |
|
RU2822890C1 |
| RECOMBINANT PLASMID DNA OF pBiPr-ABIgA2m1F16-ht TO OBTAIN RECOMBINANT IMMUNOGLOBULIN A OF ISOTYPE IgA2m1 | 2016 |
|
RU2671477C2 |
| METHOD FOR PRODUCING RECOMBINANT IGA2m1 ISOTYPE IMMUNOGLOBULIN IN MAMMALIAN CELLS | 2022 |
|
RU2801178C1 |
